Rezolute (RZLT) Preferred Stock Liabilities (2015 - 2026)
Rezolute (RZLT) posted Preferred Stock Liabilities of $483000.0 for Q1 2026, little changed sequentially from $483000.0 in Q4 2025, and little changed YoY from $483000.0 in Q1 2025.
Powered by 
Analysis
Rezolute (RZLT) Preferred Stock Liabilities (2015 - 2026) Analysis & Trends
Rezolute has reported Preferred Stock Liabilities for 9 years, with the latest figure at $483000.0 in Q1 2026.
- Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $483000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $483000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $468000.0, changed 0.0% from the prior year.
- Preferred Stock Liabilities was little changed at $483000.0 in Q1 2026 per RZLT's latest filing, from $483000.0 in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $483000.0 in Q3 2024 and troughed at $395000.0 in Q1 2022.
- A 5-year average of $450647.1 and a median of $453000.0 in 2024 frame the typical range for Preferred Stock Liabilities.
- The sharpest annual moves came in 2024 and 2025: Preferred Stock Liabilities gained 13.59% in 2024, then changed 0.0% in 2025.
- Over 5 years, Preferred Stock Liabilities stood at $434000.0 in 2022, then advanced by 1.15% to $439000.0 in 2023, then increased by 8.66% to $477000.0 in 2024, then increased by 1.26% to $483000.0 in 2025, then changed by 0.0% to $483000.0 in 2026.
- According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $483000.0, $483000.0, and $483000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Rezolute | 477.02 Mn | 477.02 Mn | - | 483,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 483,000.00 |
| Dec 31, 2025 | 483,000.00 |
| Sep 30, 2025 | 483,000.00 |
| Jun 30, 2025 | 468,000.00 |
| Mar 31, 2025 | 483,000.00 |
| Dec 31, 2024 | 477,000.00 |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | 453,000.00 |
| Dec 31, 2023 | 439,000.00 |
| Sep 30, 2023 | 426,000.00 |
| Jun 30, 2023 | 412,000.00 |
| Mar 31, 2023 | 447,000.00 |
| Dec 31, 2022 | 434,000.00 |
| Sep 30, 2022 | 420,000.00 |
| Jun 30, 2022 | 407,000.00 |
| Mar 31, 2022 | 395,000.00 |
| Dec 31, 2021 | 383,000.00 |
| Sep 30, 2021 | 371,000.00 |
| Jun 30, 2021 | 387,000.00 |